NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation adeno-associated virus (AAV) capsids generated using the University of North Carolina’s (UNC) AIMTM vector platform and that the USPTO allowed the claims of a companion patent application, which will issue in the next several weeks. Both patents are exclusively licensed by the Company from UNC.

“The issuance of these patents strengthens intellectual property around our library of AIMTM capsids that have shown potential to improve tropism profiles for a variety of devastating diseases,” said João Siffert, M.D., Chief Executive Officer. “It is also a step forward in the development of next-generation AAV technology that could make re-treatment with gene therapy possible for patients who have been previously treated using certain AAV-based vectors.”

Read full Press Release here